Log In
Print
BCIQ
Print
Print this Print this
 

Netupitant

  Manage Alerts
Collapse Summary General Information
Company Roche
DescriptionNeurokinin 1 (NK1) Substance P receptor antagonist
Molecular Target Neurokinin 1 (NK1) Substance P receptor (TACR1)
Mechanism of ActionNeurokinin-1 (NK-1) (Substance P) receptor antagonist
Therapeutic Modality 
Latest Stage of DevelopmentPhase III
Standard IndicationEmesis
Indication DetailsPrevent chemotherapy-induced nausea and vomiting (CINV)
Regulatory Designation

Partner

Helsinn Healthcare S.A.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today